Nicotinic receptor function determined by stimulation of rubidium efflux from mouse brain synaptosomes

MJ Marks, DA Farnham, SR Grady and AC Collins

Institute for Behavioral Genetics, University of Colorado, Boulder.

The ability of nicotinic agonists to activate ion channels resulting in Na+ and K+ fluxes has been used to develop a functional assay by using mouse brain synaptosomes. Synaptosomes prepared using Percoll gradients were enriched in binding sites for [3H]nicotine and were capable of accumulating the K+ analog, 86Rb+. The efflux of 86Rb+ from the synaptosomes was subsequently monitored using continuous superfusion at 21 degrees C. Ion flux was stimulated in a concentration-dependent manner by several nicotinic agonists, including L-nicotine, acetylcholine, N-methylcarbamylcholine and dimethylphenylpiperazinium. The process was stereoselective: L-nicotine was 30-fold more potent than D-nicotine. Cytisine stimulated ion flux at low concentrations, but this drug was less efficacious than most other agonists tested. Anabasine was also less efficacious than the other agonists. The EC50 values for agonist-stimulated efflux correlated closely to the IC50 values for inhibition of [3H]nicotine binding, but concentrations required to inhibit binding were lower than those required to stimulate ion flux. Nicotine-induced 86Rb+ efflux was blocked by several nicotinic antagonists including mecamylamine, D-tubocurarine, hexamethonium and decamethonium. Mecamylamine was approximately 50 times as potent as hexamethonium. Neither alpha-bungarotoxin nor atropine were effective antagonists and neuronal-bungarotoxin was a relatively ineffective inhibitor. The amount of nicotine-induced efflux varied among brain regions with midbrain (thalamus and mesencephalon) having the largest response and cerebellum the smallest. The magnitude of the ion flux correlated closely with the amount of [3H] nicotine binding in each brain region. The results indicate that a nicotinic- receptor-mediated ion flux can be measured in brain tissue and that the ion flux may serve as a useful functional assay for nicotinic receptors in the central nervous system. Furthermore, it is postulated that the nicotinic-agonist stimulated ion flux may be mediated by receptors measured by high affinity [3H]nicotine binding.

Volume 264, Issue 2, pp. 542-552, 02/01/1993
Copyright © 1993 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				D. Kota, B. R. Martin, S. E. Robinson, and M. I. Damaj Nicotine Dependence and Reward Differ between Adolescent and Adult Male Mice J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 399 - 407. [Abstract] [Full Text] [PDF]

				A. F. Britton, R. E. Vann, and S. E. Robinson Perinatal Nicotine Exposure Eliminates Peak in Nicotinic Acetylcholine Receptor Response in Adolescent Rats J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 871 - 876. [Abstract] [Full Text] [PDF]

				C. A. Briggs, E. J. Gubbins, M. J. Marks, C. B. Putman, R. Thimmapaya, M. D. Meyer, and C. S. Surowy Untranslated Region-Dependent Exclusive Expression of High-Sensitivity Subforms of {alpha}4beta2 and {alpha}3beta2 Nicotinic Acetylcholine Receptors Mol. Pharmacol., July 1, 2006; 70(1): 227 - 240. [Abstract] [Full Text] [PDF]

				D. K. Miller, P. A. Crooks, G. Zheng, V. P. Grinevich, S. D. Norrholm, and L. P. Dwoskin Lobeline Analogs with Enhanced Affinity and Selectivity for Plasmalemma and Vesicular Monoamine Transporters J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1035 - 1045. [Abstract] [Full Text] [PDF]

				P. Dobelis, M. J. Marks, P. Whiteaker, S. A. Balogh, A. C. Collins, and J. A. Stitzel A Polymorphism in the Mouse Neuronal alpha 4 Nicotinic Receptor Subunit Results in An Alteration in Receptor Function Mol. Pharmacol., August 1, 2002; 62(2): 334 - 342. [Abstract] [Full Text] [PDF]

				E. L. Meyer, L. C. Gahring, and S. W. Rogers Nicotine Preconditioning Antagonizes Activity-dependent Caspase Proteolysis of a Glutamate Receptor J. Biol. Chem., March 22, 2002; 277(13): 10869 - 10875. [Abstract] [Full Text] [PDF]

				C. G. V. Sharples, S. Kaiser, L. Soliakov, M. J. Marks, A. C. Collins, M. Washburn, E. Wright, J. A. Spencer, T. Gallagher, P. Whiteaker, et al. UB-165: A Novel Nicotinic Agonist with Subtype Selectivity Implicates the alpha 4beta 2* Subtype in the Modulation of Dopamine Release from Rat Striatal Synaptosomes J. Neurosci., April 15, 2000; 20(8): 2783 - 2791. [Abstract] [Full Text] [PDF]

				M. J. Marks, P. Whiteaker, J. Calcaterra, J. A. Stitzel, A. E. Bullock, S. R. Grady, M. R. Picciotto, J.-P. Changeux, and A. C. Collins Two Pharmacologically Distinct Components of Nicotinic Receptor-Mediated Rubidium Efflux in Mouse Brain Require the beta 2 Subunit J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 1090 - 1103. [Abstract] [Full Text]

				Y. Lu, S. Grady, M. J. Marks, M. Picciotto, J.-P. Changeux, and A. C. Collins Pharmacological Characterization of Nicotinic Receptor-stimulated GABA Release From Mouse Brain Synaptosomes J. Pharmacol. Exp. Ther., November 1, 1998; 287(2): 648 - 657. [Abstract] [Full Text]

				M. Bencherif, J. D. Schmitt, B. S. Bhatti, P. Crooks, W. S. Caldwell, M. E. Lovette, K. Fowler, L. Reeves, and P. M. Lippiello The Heterocyclic Substituted Pyridine Derivative (±)-2-(-3-pyridinyl)-1-Azabicyclo[2.2.2]octane (RJR-2429): A Selective Ligand at Nicotinic Acetylcholine Receptors J. Pharmacol. Exp. Ther., March 1, 1998; 284(3): 886 - 894. [Abstract] [Full Text]

				K. A. Stauderman, L. S. Mahaffy, M. Akong, G. Veliçelebi, L. E. Chavez-Noriega, J. H. Crona, E. C. Johnson, K. J. Elliott, A. Gillespie, R. T. Reid, et al. Characterization of Human Recombinant Neuronal Nicotinic Acetylcholine Receptor Subunit Combinations alpha 2beta 4, alpha 3beta 4 and alpha 4beta 4 Stably Expressed in HEK293 Cells J. Pharmacol. Exp. Ther., February 1, 1998; 284(2): 777 - 789. [Abstract] [Full Text]

				J. P. Sullivan, D. Donnelly-Roberts, C. A. Briggs, D. J. Anderson, M. Gopalakrishnan, I. C. Xue, M. Piattoni-Kaplan, E. Molinari, J. E. Campbell, D. G. Mckenna, et al. ABT-089 [2-Methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A Potent and Selective Cholinergic Channel Modulator with Neuroprotective Properties J. Pharmacol. Exp. Ther., October 1, 1997; 283(1): 235 - 246. [Abstract] [Full Text]

				M. I. Damaj, W. Glassco, M. J. Marks, B. Slobe, J. R. James, E. L. May, J. A. Rosecrans, A. C. Collins, and B. R. Martin Pharmacological Investigation of (+)- and (-)-cis-2,3,3a,4,5,9b-Hexahydro-1-methyl-1H-pyrrolo[3,2-h]isoquinoline, a Bridged-Nicotine Analog J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1425 - 1434. [Abstract] [Full Text]

				S. R. Grady, E. U. Grun, M. J. Marks, and A. C. Collins Pharmacological Comparison of Transient and Persistent [3H]Dopamine Release from Mouse Striatal Synaptosomes and Response to Chronic L-Nicotine Treatment J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 32 - 43. [Abstract] [Full Text]